. 2021 Jan 29;71(2):140–152. doi: 10.1111/idj.12607

Table 2.

Bivariate analysis of factors associated with subscale and total scores of the OHIP-14 in patients with OLP (N = 300)

Study variables	FL		PhyP		PsyD		PhyDis		PsyDis		SD		H		Total score
Study variables	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P	Med (IQR)	P value
Gender^†
Female	2 (0, 3)	0.224	4 (3, 6)	0.328	2 (1, 4)	0.057	3 (1, 5)	0.331	2 (0, 4)	0.042	1 (0, 3)	0.16	1 (0, 3)	0.166	15 (8, 26)	0.085
Male	1 (0, 3)		4 (3, 6)		2 (0, 4)		2 (0, 4)		1 (0, 3)		1 (0, 2)		1 (0, 2)		11 (5, 21)
Ethnicity^‡
White^¶	1 (0, 3)	0.014	4 (3, 6)	0.007	2 (1, 4)	0.177	2 (0, 4)	0.000^*	1 (0, 3)	0.002^*	1 (0, 3)	0.24	1 (0, 2)	0.016	13 (7, 22)	0.001^*
Mixed	1 (0, 2)		4 (3, 6)	^¶^*	2 (0, 4)		1 (0, 4)		2 (0, 3)		1 (0, 2)		1 (0, 2)		12 (4, 23)	^¶^*
Asian	2 (0, 4)	^¶	5 (4, 7)	^¶^*	3 (1, 6)		4 (2, 6)	^¶^,^*	2 (1, 5)	^¶	1 (0, 4)		2 (0, 4)	^¶^,^*	20 (11, 33)	^¶^*
Black	3 (1, 5)		6 (3, 7)		2 (1, 8)		5 (2, 8)		3 (2, 7)	^¶	2 (0, 2)		1 (0, 3)		26 (10, 39)
Smoking^‡
Non-smoker	1 (0, 3)	0.291	4 (3, 6)	0.724	2 (1, 4)	0.276	2 (0, 4)	0.672	2 (0. 3)	0.271	1 (0, 3)	0.352	1 (0, 2)	0.474	15 (7, 25)	0.451
Ex-smoker	2 (0, 3)		4 (3, 6)		2(1, 5)		3 (1, 5)		2 (0, 4)		1 (0, 3)		1 (0, 2)		15 (9, 27)
Current smoker Alcohol^‡	2 (0, 4)		4 (4, 7)		4 (0, 7)		3 (1, 6)		3 (1, 6)		2 (0, 5)		2 (0, 6)		19 (5, 43)
No^¶	2 (0, 4)	0.008	5 (4, 6)	0.042	3 (1, 5)	0.195	4 (2, 6)	0.000^*	2 (0, 4)	0.028	1 (0, 4)	0.014	1 (0, 3)	0.269	19 (9, 33)	0.007
≤ 14 units/week	1 (0, 3)		4 (3, 6)		2 (1, 4)		2 (0, 4)		2 (0, 3)		1 (0, 3)		1 (0, 2)		14 (8, 23)	^¶
> 14 units/week Co-morbidity^‡	1 (0, 2)	^¶	4 (2, 5)		3 (0, 4)		1 (0, 3)	^¶^,^*	1 (0, 2)	^¶	0 (0, 1)	^¶	1 (0, 2)		12 (5, 18)	^¶
> 14 units/week Co-morbidity^‡	1 (0, 2)	^¶	4 (2, 5)		3 (0, 4)		1 (0, 3)	^¶^,^*	1 (0, 2)	^¶	0 (0, 1)	^¶	1 (0, 2)		12 (5, 18)	^¶,^*
No^¶	(0, 2)	0.013	4 (2, 5)	0.01	2 (1, 4)	0.42	2 (0, 4)	0.044	2 (0, 3)	0.03	1 (0, 3)	0.496	1 (0, 2)	0.026	13 (5, 21)	0.03
1 co-morbidity^††	1 (0, 2)		4 (3, 5)		2 (1, 4)		2 (1, 4)		1 (0, 2)		1 (0, 2)		1 (0, 2)		13 (7, 22)
≥ 2 co-morbidities Clinical types^* Keratotic^¶	2 (0, 4)		5 (3, 6)		2 (1, 5)		3 (1, 5)		2 (0, 4)	^‡	1 (0, 3)		1 (0, 3)		17 (8, 29)
≥ 2 co-morbidities Clinical types^* Keratotic^¶	1 (0, 2)	0.116	4 (2, 4)	0.000^*	2 (0, 4)	0.084	1 (0, 3)	0.006	1 (0, 3)	0.129	0 (0, 2)	0.001^*	1 (0, 2)	0.082	10 (4, 21)	0.006^*
Erythematous^††	2 (0, 3)		4 (3, 6)		3 (1, 4)		3 (1, 4)	¶	2 (0, 4)		1 (0, 3)		1 (0, 2)		15 (8, 24)	¶,^*
Erosive/ulcerative Extraoral LP^¶	2 (0, 3)		6 (4, 7)	^¶,^*,^††	3 (1, 5)		4 (2, 5)	^*	2 (1, 5)		2 (1, 4)	^¶^,^^,^††^,^	2 (1, 3)		20 (11, 31)	¶,^*
Erosive/ulcerative Extraoral LP^¶	2 (0, 3)		6 (4, 7)		3 (1, 5)		4 (2, 5)		2 (1, 5)		2 (1, 4)		2 (1, 3)		20 (11, 31)
No	1 (0, 3)		4 (3, 6)		2 (0, 4)		2 (0, 4)		2 (0, 3)		1 (0, 3)		1 (0, 2)		15 (7, 24)
Yes/genital	2 (0, 4)	0.54	4 (4, 6)	0.302	3 (2, 5)	0.054	3 (0, 6)	0.388	2 (1, 4)	0.09	1 (0, 3)	0.603	1 (0, 3)	0.535	15 (7, 29)	0.3
Yes/skin Treatment^‡ No/only Tanes^¶ TCS alone^††	2 (1, 4)	0.06	5 (3, 7)	0.16	3 (2, 5)	0.01	4 (2, 6)	0.003^*	3 (1, 4)	0.06	2 (1, 3)	0.03	2 (0, 4)	0.115	20 (12, 33)	0.01
	0 (0, 1)	0.000^*	2 (0, 4)	0.000^*	1 (0, 2)	0.000^*	0 (0, 2)	0.000^*	0 (0, 1)	0.000^*	0 (0, 1)	0.000^*	0 (0, 1)	0.000^*	5 (2, 10)	0.000^*
	2 (0, 3)	^¶,^*	4 (3, 6)	^¶,^*	2 (1, 5)	^¶,^*	3 (1, 4)	^¶,^*	2 (0, 4)	^¶,^*	1 (0, 3)		1 (0, 2)		16 (8, 24)
TCS + other TTx	3 (1, 4)	^¶,^*^,^††	6 (4, 7)	^¶,^*^,^††	4 (2, 5)	^¶,^*	4 (3, 6)	^¶,^*^,^††	3 (1, 4)	^¶,^*^,^††	2 (1, 4)	^¶,^*	2 (1, 3)	^¶,^*	22 (13, 30)	^¶,^*^,^††
TTx + STx	3 (0, 4)	^¶	5 (4, 7)	^¶,^*	2 (0, 4)		3 (1, 6)	^¶,^*	3 (1, 4)	^¶	3 (0, 6)	^¶,^*	2 (1, 4)	^¶	21 (6, 36)
Age (years)^§	–0.065	0.262	–0.074	0.2	–0.188	0.001^*	–0.078	0.179	–0.125	0.031	–0.138	0.017	-0.087	0.131	–0.137	0.018
Disease duration (years)^§	0.038	0.507	0.065	0.262	–0.034	0.564	–0.042	0.474	–0.032	0.586	–0.026	0.651	-0.013	0.825	–0.017	0.766
NRS for pain^§	0.49	0.000^*	0.632	0.000^*	0.461	0.000^*	0.588	0.000^*	0.526	0.000^*	0.477	0.000^*	0.455	0.000^*	0.622	0.000^*
HADS-Anxiety^§	0.429	0.000^*	0.377	0.000^*	0.465	0.000^*	0.394	0.000^*	0.536	0.000^*	0.446	0.000^*	0.52	0.000^*	0.534	0.000^*
HADS-Depression^§ HADS-total^§	0.432	0.000^*	0.386	0.000^*	0.461	0.000^*	0.427	0.000^*	0.493	0.000^*	0.419	0.000^*	0.481	0.000^*	0.528	0.000^*
HADS-Depression^§ HADS-total^§	0.468	0.000^*	0.42	0.000^*	0.513	0.000^*	0.442	0.000^*	0.567	0.000^*	0.473	0.000^*	0.551	0.000^*	0.583	0.000^*
PSS-10^§	0.366	0.000^*	0.383	0.000^*	0.453	0.000^*	0.37	0.000^*	0.508	0.000^*	0.45	0.000^*	0.475	0.000^*	0.508	0.000^*
ODSS total^§	0.381	0.000^*	0.534	0.000^*	0.378	0.000^*	0.482	0.000^*	0.369	0.000^*	0.373	0.000^*	0.326	0.000^*	0.494	0.000^*
ODSS-site^§	0.272	0.000^*	0.355	0.000^*	0.266	0.000^*	0.349	0.000^*	0.254	0.000^*	0.237	0.000^*	0.211	0.000^*	0.343	0.000^*
ODSS-activity^§	0.307	0.000^*	0.448	0.000^*	0.313	0.000^*	0.4	0.000^*	0.286	0.000^*	0.319	0.000^*	0.271	0.000^*	0.405	0.000^*
All subjects	2 (0, 3)		4 (3, 6)		2 (1, 4)		2 (0, 4.5)		2 (0, 4)		1 (0, 3)		1 (0, 2)		15 (7, 25)

Bold value = P-value < 0.05.

STx, systemic treatment; Tanes, topical anaesthetic agents; TCS, topical corticosteroids; TTx, topical treatment.

^†

Mann–Whitney U-test.

^‡

Kruskal–Wallis test.

^§

Spearman's rho correlation coefficients.

^¶

Significant difference with the first reference group.

^††

Significant difference with the second reference group.

^⁎

Statistical significance at Bonferroni-corrected P-value of 0.003.